| abstract |
Use of the antiprogestin 11.beta .- (4-acetylphenyl) -17.beta.-hydroxy-17.alpha .- (1,1,2,2,2-pentafluoroethyl) estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analog thereof for the preparation of a medicament for the treatment of a type of cancer selected from the group consisting of breast cancer, ovarian cancer, endometrial cancer, myeloma and meningioma with high risk S-phase tumor cells by inducing apoptosis by administering said antiprogestin or pharmaceutically acceptable derivative thereof or an analogue in a daily dose of 0.1 to 400 mg / kg. |